Welcome to our dedicated page for Evoke Pharma news (Ticker: EVOK), a resource for investors and traders seeking the latest updates and insights on Evoke Pharma stock.
Evoke Pharma Inc (EVOK) is a biotechnology innovator focused on advancing treatments for gastrointestinal disorders, notably through its FDA-approved GIMOTI® nasal spray for diabetic gastroparesis. This page provides investors and healthcare professionals with essential updates on the company's strategic initiatives, clinical developments, and market progress.
Access real-time announcements including regulatory milestones, financial results, and partnership agreements that shape Evoke's position in specialty pharmaceuticals. Our curated news feed covers critical updates such as prescription adoption trends, distribution network expansions, and intellectual property developments related to nasal drug delivery technologies.
Key areas of coverage include GIMOTI commercialization progress, pharmacy network partnerships, and operational efficiency initiatives. Bookmark this page to stay informed about Evoke Pharma's advancements in addressing unmet needs in gastrointestinal care through its non-oral therapeutic solutions.
Evoke Pharma (NASDAQ: EVOK) has announced significant expansion of access to its GIMOTI® nasal spray through new strategic partnerships. The company has secured relationships with Omnicell (NASDAQ: OMCL) and Brentwood Pharmacy, which will substantially increase GIMOTI's availability through specialty pharmacy networks.
The Omnicell partnership will facilitate GIMOTI distribution to major gastroenterology organizations, including Gastro Health (150 locations across 7 states) and OneGI (200+ gastroenterologists across multiple states). These partnerships are expected to nearly double the number of specialty pharmacies with access to GIMOTI, the only FDA-approved nasal spray for adults with acute and recurrent diabetic gastroparesis.
Evoke Pharma (NASDAQ: EVOK) has announced the listing of a new patent (U.S. Patent No. 12,377,064) for GIMOTI® (metoclopramide) nasal spray in the FDA's Orange Book. The patent covers the use of GIMOTI® in treating patients with moderate to severe gastroparesis symptoms.
The newly listed patent extends protection until November 17, 2038, approximately eight years beyond their previous patent expiration date of May 15, 2030. This strategic move strengthens Evoke's position in providing non-oral treatment options for diabetic gastroparesis while protecting their innovation investment.
Evoke Pharma (NASDAQ: EVOK) reported strong Q2 2025 financial results, with net product sales surging 47% year-over-year to $3.8 million for their gastroparesis treatment GIMOTI. The company experienced significant growth with a 20% increase in new prescribers and maintained a robust 70% refill rate.
Despite growing sales, Evoke posted a net loss of $1.6 million ($0.62 per share) compared to $1.3 million in Q2 2024. Operating expenses increased to $5.3 million, up from $3.8 million year-over-year. The company maintains a healthy cash position of $12.1 million and expects funding to last through Q3 2026.
Evoke confirmed its full-year 2025 revenue guidance of $16 million, representing a potential 60% increase over 2024, driven by prescription growth and expanded pharmacy access.
Evoke Pharma (NASDAQ: EVOK) has secured a new U.S. patent (No. 12,377,064) for its product GIMOTI®, a nasal spray treatment for gastroparesis. The United States Patent and Trademark Office has extended the patent term to November 2038, providing nearly two additional years of market exclusivity beyond the previous December 2036 expiration.
The patent specifically covers the use of intranasal metoclopramide for patients with moderate to severe gastroparesis symptoms. The company plans to list this patent in the FDA's Orange Book to strengthen GIMOTI's intellectual property position and is pursuing additional related claims through a continuation application.
Evoke Pharma (NASDAQ: EVOK) has received a Notice of Allowance from the USPTO for a patent application covering GIMOTI® (metoclopramide nasal spray) use in moderate to severe gastroparesis patients. The new patent, upon issuance, will extend market exclusivity until December 2036 and will be listed in the FDA's Orange Book.
GIMOTI® is the only FDA-approved, non-oral, self-administered metoclopramide formulation for treating symptoms of acute and recurrent diabetic gastroparesis in adults. The treatment is particularly valuable as gastroparesis can impair the absorption of oral medications. The company has filed an additional U.S. continuation application for further claims related to this patient population.
Evoke Pharma (NASDAQ: EVOK) reported strong Q1 2025 financial results, with net product sales increasing 77% year-over-year to $3.1 million. The company's performance was driven by significant growth in GIMOTI adoption, achieving a 73% increase in fill rate and 44% growth in total prescriber base compared to Q1 2024.
The company reported a net loss of $1.3 million ($0.51 per share), improved from $1.6 million loss in Q1 2024. Operating expenses increased to $4.4 million, up from $3.2 million in the same period last year. With $12.6 million in cash and cash equivalents, Evoke expects to fund operations into Q2 2026.
Evoke maintains its 2025 net product sales guidance of approximately $16 million, representing a 60% increase over 2024. The company also appointed Greg Pyszczymuka to its Board of Directors to strengthen commercial strategy.
Evoke Pharma (NASDAQ: EVOK) has announced the acceptance of a new abstract for presentation at Digestive Disease Week® (DDW) 2025, scheduled for May 3-6, 2025, in San Diego. The research compares tardive dyskinesia (TD) incidence in patients receiving continuous versus intermittent oral metoclopramide treatment.
The analysis, based on real-world data from over 100 million U.S. patients, examines TD incidence rates and timing related to different metoclopramide dosing patterns. The presentation, led by Dr. Pierantonio Russo from EVERSANA Life Sciences, is scheduled for May 5, 2025, from 12:30-1:30 p.m. PT.
CEO Matt D'Onofrio emphasized the importance of understanding metoclopramide's long-term safety profile, particularly for GIMOTI®, the only FDA-approved treatment for diabetic gastroparesis. The abstract will be available through the DDW ePosters site and meeting planner after May 4, 2025. Visitors can learn more at Evoke Pharma's booth #917 during the conference.
Evoke Pharma (NASDAQ: EVOK) reported strong financial results for Q4 and full-year 2024. Q4 revenue increased 24.6% to $3.3 million compared to Q3 2024, while full-year revenue grew 97.8% to $10.2 million year-over-year.
Key achievements include:
- 46% growth in prescriber base to 2,553 total prescribers
- 72% increase in fill rates year-over-year
- 22% rise in patient enrollments
- $14.3 million raised through equity financings
- Cash runway extended into Q1 2026
The company's GIMOTI treatment for diabetic gastroparesis gained further validation through award-winning research presented at ACG 2024, particularly highlighting benefits for GLP-1 users. Evoke projects 2025 net revenue of approximately $16 million, representing a 60% increase from 2024.
Evoke Pharma (NASDAQ: EVOK), a specialty pharmaceutical company focused on gastrointestinal diseases and maker of Gimoti® nasal spray, has scheduled its fourth quarter and full year 2024 financial results release for Thursday, March 13, 2025, after market close.
Management will host a conference call and webcast with slides at 4:30 p.m. ET on the same day. Investors can join via phone using domestic dial-in (800) 267-6316 or international (203) 518-9783, with conference ID EVOKQ424. A replay will be available until March 20, 2025, accessible at (800) 723-0544 for domestic and (402) 220-2656 for international callers.
Evoke Pharma (NASDAQ: EVOK) has appointed Greg Pyszczymuka to its Board of Directors, effective February 20, 2025. This is the second board member appointment by Nantahala Capital Management, showing their continued confidence in Evoke's strategy. Pyszczymuka, currently Chief Commercial Officer at Aytu BioPharma, brings extensive experience in pharmaceutical sales and market access.
Under his leadership at Aytu, the company achieved operational profitability and sustainable revenue growth. His 20-year career includes senior roles at Neos Therapeutics, Aqua Pharmaceuticals, Iroko Pharmaceuticals, Zogenix, and Endo Pharmaceuticals. The appointment aims to strengthen Evoke's market presence and enhance shareholder value, particularly in expanding access to GIMOTI®, their metoclopramide nasal spray for gastrointestinal diseases.
FAQ
What is the current stock price of Evoke Pharma (EVOK)?
What is the market cap of Evoke Pharma (EVOK)?
